Drug General Information (ID: DDI8ZORI73)
Drug Name			Daptomycin		Drug Info		Gemfibrozil		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antibiotics				Antihyperammonia Agents
Structure

Mechanism of Daptomycin-Gemfibrozil Interaction (Severity Level: Moderate)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Daptomycin				Gemfibrozil
Mechanism		Rhabdomyolysis				Rhabdomyolysis
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Daptomycin and Gemfibrozil

Recommended Action
Management		Due to the limited nature of existing data, consideration should be given to temporarily suspending use of fibrates in patients receiving daptomycin. All patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more).

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".